Oestrogen promotes the progression of adenomyosis by inhibiting CITED2 through miR-145
Reproductive BioMedicine Online · 2024
DOI: 10.1016/j.rbmo.2024.104108 ↗Kurz gefasst
Fachartikel in der Zeitschrift Reproductive BioMedicine Online, 2024. Verfasst von Ziyu Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Jiangxi Maternal and Child Health Hospital, 330006 Nanchang, Jiangxi, PR China; The Subcenter of National Clinical Research …. Hauptthemen laut MEDLINE: MicroRNAs, Adenomyosis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
RESEARCH QUESTION: Is the microRNA miR-145 involved in adenomyosis, and by what mechanisms does it affect disease development and is itself regulated? DESIGN: Fluorescence in-situ hybridization was used to observe the expression pattern of miR-145 in adenomyosis ectopic endometrium (n = 13), adenomyosis eutopic endometrium (n = 15) and non-adenomyosis eutopic endometrium (n = 14). RNA sequencing was used to screen target genes as well as downstream pathways of miR-145, which were validated by reporter gene assay, quantitative polymerase chain reaction and western blot, and further analysed using cell migration assay and chromatin immunoprecipitation assay. RESULTS: The fluorescence in-situ hybridization assay revealed a noteworthy elevation in miR-145 expression in adenomyosis tissue compared with non-adenomyosis tissue. Furthermore, RNA sequencing analysis revealed that overexpression of miR-145 resulted in heightened expression of genes associated with the cytokine signalling pathway, nucleotide-binding and oligomerization domain-like pathway and adhesion pathway, including IL-1β and IL-6. Our study has identified CITED2 as a downstream direct target gene of miR-145, which is implicated in the inhibition of stromal cell migration induced by miR-145. Moreover, chromatin immunoprecipitation was used to validate the direct effect of oestradiol on the promoter region of miR-145, mediated by oestrogen receptor α, which facilitates the upregulation of miR-145 expression. CONCLUSION: Our findings provide evidence supporting the role of oestradiol, acting through its receptor α, in modulating the discovered miR-145-CITED2 signalling axis, thereby promoting the progression of adenomyosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Jiangxi Maternal and Child Health Hospital, 330006 Nanchang, Jiangxi, PR China; The Subcenter of National Clinical Research Center for Obstetrics and Gynecology, Jiangxi Maternal and Child Healt…
- Department of Pathology, Jiangxi Maternal and Child Health Hospital, 330006 Nanchang, Jiangxi, PR China.
- Department of Gynaecology, Jiangxi Maternal and Child Health Hospital, 330006 Nanchang, Jiangxi, PR China.
- Jiujiang Blood Central, Jiujiang, Jiangxi, PR China. Electronic address: drj@sina.com.
- Department of Gynaecology, Jiangxi Maternal and Child Health Hospital, 330006 Nanchang, Jiangxi, PR China. Electronic address: wangliqun992000@163.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, Z., Qin, Y., Huang, J., Wang, Y., Zeng, L., Wang, Y., Zhuyun, F., & Wang, L. (2024). Oestrogen promotes the progression of adenomyosis by inhibiting CITED2 through miR-145. Reproductive BioMedicine Online. https://doi.org/10.1016/j.rbmo.2024.104108
Vancouver
Zhang Z, Qin Y, Huang J, Wang Y, Zeng L, Wang Y, et al. Oestrogen promotes the progression of adenomyosis by inhibiting CITED2 through miR-145. Reproductive BioMedicine Online. 2024. doi:10.1016/j.rbmo.2024.104108
BibTeX
@article{Zhang2024,
author = {Zhang, Ziyu and Qin, Yunna and Huang, Jia and Wang, Yaoqing and Zeng, Liqin and Wang, Yuanqin and Zhuyun, Fu and Wang, Liqun},
title = {Oestrogen promotes the progression of adenomyosis by inhibiting CITED2 through miR-145},
journal = {Reproductive BioMedicine Online},
year = {2024},
doi = {10.1016/j.rbmo.2024.104108}
}
EUVIMED